Genentech, Inc.
NEWS
Here’s a look at the top 10 companies noted in the BioSpace Ideal Employer 2019 survey for being the most innovative and what they’ve been up to recently.
Amunix Pharmaceuticals, based in Mountain View, California, entered a licensing deal with Roche. Under the terms of the deal, Roche will pay Amunix $40 million upfront.
Arcus Biosciences and Genentech, a Roche company, are partnering on two clinical trials for colorectal and pancreatic cancer. They will evaluate Arcus’s AB928 in various combinations.
Similar to the Biotech Bay list, BioSpace takes a look at the top 10 2019 Life Sciences Ideal Employer Report’s for Genetown.
It was, as usual, a pretty busy week in clinical trial news. Here’s a look.
The U.S. Food and Drug Administration approved Genentech’s Tecentriq plus chemotherapy as a first-line treatment of metastatic non-squamous non-small cell lung cancer.
Even with a shortened week due to the U.S. Thanksgiving holiday, there was plenty of clinical trial news and updates. Here’s a look.
Tecentriq is the company’s PD-L1 checkpoint inhibitor. Avastin is an antibody that binds to VEGF and interferes with tumor blood supply.
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
JOBS
IN THE PRESS